Gene-guided Warfarin for Anticoagulation Therapy

• Status: Withdrawn
• Trial end date: 2021-08-20
• Target enrollment: 0
• Participant gender: All

Summary

This study will explore the effect of warfarin gene polymorphism on the effectiveness and safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the correlation between genetic testing and compliance rate of INR value. It will illustrate the significance of gene-guided warfarin for administered dose to anticoagulation therapy in patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose prediction model suitable for such patients, and provide basis for the personalized medication regimen of warfarin in patients with acute ischemic stroke.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Warfarin

Criteria

Inclusion Criteria:

• Patients with acute ischemic stroke aged ≥18 years (cardiogenic cerebral embolism patients)

• Clinicians judge that long-term oral anticoagulation with warfarin is required

• No anticoagulation treatment in the past 10 days

• Agree to participate in this project

Exclusion Criteria:

• Patients who had a tendency to bleed when taking warfarin

• High-risk groups using warfarin anticoagulation